Security
Radiopharm Theranostics Limited American Depositary Shares · RADX
RADXNASDAQotherCurrentCIK 1949257Updated Oct 15, 2026
RADX price & chart
Loading TradingView…
NASDAQ:RADX on TradingView ↗About the company
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, prostate and brain. Learn more at radiopharmtheranostics.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 |
|---|---|
| Cash flows from operating activities: | |
| Profit or LossUSD | -38,342,457Source |
| Additional Financial Items | |
| AdjustmentsForFinanceCostsUSD | -285Source |
| AdjustmentsForFinanceIncomeUSD | -888,196Source |
| AdjustmentsForSharebasedPaymentsUSD | 1,895,348Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -138,141Source |
| GeneralAndAdministrativeExpenseUSD | 14,638,013Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 800,309Source |
| ProceedsFromIssuingSharesUSD | 53,977,902Source |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Cost of Goods and Services Sold | —Source |
| Total RevenueUSD | 3,633,422Source |
| Additional Financial Items | |
| BasicEarningsLossPerShareUSD per share | -1.76Source |
| CurrentTaxExpenseIncomeUSD | 103,292Source |
| DilutedEarningsLossPerShareUSD per share | -1.76Source |
| FinanceCostsUSD | 65,300Source |
| GeneralAndAdministrativeExpenseUSD | 14,638,013Source |
| GrossProfitUSD | 39,276Source |
| IncomeTaxExpenseContinuingOperationsUSD | 103,292Source |
| OtherIncomeUSD | 10,256,740Source |
| ProfitLossBeforeTaxUSD | -38,239,165Source |
| ProfitLossFromOperatingActivitiesUSD | -38,173,865Source |
| ResearchAndDevelopmentExpenseUSD | 27,515,194Source |
Offerings
Registration 333-298912
Filing attachments
ea030767001ex99-1.htm · 6-K · 2026-10-05
Exhibit 99.1 ASX ANNOUNCEMENT October 5, 2026 ─────────────────── Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101 Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in next 30 days Sydney, Australia - October 5, 2026 - Radiopharm Ther…
Read attachment ↗ea030731701ex99-1.htm · 6-K · 2026-10-01
Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 ─────────────────────────────────────────────── Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: …
Read attachment ↗ea030731701ex99-2.htm · 6-K · 2026-10-01
Exhibit 99.2 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Thursday October 01, 2026 Details of +securities that have ceased ASX Security description Number The +securities have ceased due to Date of cessation +security …
Read attachment ↗ea030684201ex4-25.htm · 20-F · 2026-09-30
Exhibit 4.25 CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL THIRD AMENDMENT TO THE LIMITED LIABILITY COMPANY AGREEMENT This Third Amendment (this “Third Amendment”), effective this 15th day of October, 2025 (the “Third Amendment Effective Date”), to the Limited Liability Company Agreeme…
Read attachment ↗ea030718701ex99-1.htm · 6-K · 2026-09-30
Exhibit 99.1 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Radiopharm Theranostics Limited ABN/ARBN Financial year ended: 57 647 877 889 30 June 2026 ───────────────────────────────────────────── Our corporate governance statement 1 for the period above can be found at: 2 These pages of our annual report: This URL on our website: www.radiopharmtheranostics.com/investors The …
Read attachment ↗ea030617901ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name Radiopharm of Entity: Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX th…
Read attachment ↗